Loading…
Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial
Purpose In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophy...
Saved in:
| Published in: | European journal of nutrition 2019-06, Vol.58 (4), p.1735-1745 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c372t-4245c9f6d5e7f25fced7af1f5234020f703bdb99c9fdfd1d507c734fb9171bc23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c372t-4245c9f6d5e7f25fced7af1f5234020f703bdb99c9fdfd1d507c734fb9171bc23 |
| container_end_page | 1745 |
| container_issue | 4 |
| container_start_page | 1735 |
| container_title | European journal of nutrition |
| container_volume | 58 |
| creator | Bomhof, Marc R. Parnell, Jill A. Ramay, Hena R. Crotty, Pam Rioux, Kevin P. Probert, Chris S. Jayakumar, Saumya Raman, Maitreyi Reimer, Raylene A. |
| description | Purpose
In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophysiology of NASH is unknown, it is believed that the gut microbiota-liver axis influences the development of this disease. With few treatment strategies available for NASH, exploration of gut microbiota-targeted interventions is warranted. We investigated the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH.
Methods
In a placebo-controlled, randomized pilot trial, 14 individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] were randomized to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. The primary outcome measure was the change in liver biopsy NAS score and the secondary outcomes included changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota.
Results
Independent of weight loss, oligofructose improved liver steatosis relative to placebo and improved overall NAS score (
P
= 0.016).
Bifidobacterium
was enhanced by oligofructose, whereas bacteria within
Clostridium
cluster XI and I were reduced with oligofructose (
P
|
| doi_str_mv | 10.1007/s00394-018-1721-2 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2042230632</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2041231540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-4245c9f6d5e7f25fced7af1f5234020f703bdb99c9fdfd1d507c734fb9171bc23</originalsourceid><addsrcrecordid>eNp1kUFPwyAUx4nRuDn9AF5MEy9eqg9oi_VmFnUmS7zomVAKGwstE6jGb29rpyYmnoC8Hz9474_QKYZLDMCuAgAtsxTwdYoZwSnZQ1Oc0SItCM73f_bAJugohA0AEFrgQzQhJWMlZjBF1cKE6KxbGSlsYpqtd2-qUW1MnE5a16bCSrd21sgkRCWiW6utiCaakLybuE5EsvWqMi4aeTMcjHUxkda0X77ojbDH6EALG9TJbp2hl_u75_kiXT49PM5vl6mkjMQ0I1kuS13UuWKa5FqqmgmNdU5oBgQ0A1rVVVn2TK1rXOfAJKOZrvpGcCUJnaGL0dv38NqpEHljglTWila5LnACGSEUCjqg53_Qjet82_9uoDChOM-gp_BISe9C8ErzrTeN8B8cAx8C4GMAvA-ADwHwwXy2M3dVo-qfG98T7wEyAqEvtSvlf5_-3_oJ30-RWA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2041231540</pqid></control><display><type>article</type><title>Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial</title><source>Springer Nature</source><source>SPORTDiscus with Full Text</source><creator>Bomhof, Marc R. ; Parnell, Jill A. ; Ramay, Hena R. ; Crotty, Pam ; Rioux, Kevin P. ; Probert, Chris S. ; Jayakumar, Saumya ; Raman, Maitreyi ; Reimer, Raylene A.</creator><creatorcontrib>Bomhof, Marc R. ; Parnell, Jill A. ; Ramay, Hena R. ; Crotty, Pam ; Rioux, Kevin P. ; Probert, Chris S. ; Jayakumar, Saumya ; Raman, Maitreyi ; Reimer, Raylene A.</creatorcontrib><description>Purpose
In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophysiology of NASH is unknown, it is believed that the gut microbiota-liver axis influences the development of this disease. With few treatment strategies available for NASH, exploration of gut microbiota-targeted interventions is warranted. We investigated the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH.
Methods
In a placebo-controlled, randomized pilot trial, 14 individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] were randomized to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. The primary outcome measure was the change in liver biopsy NAS score and the secondary outcomes included changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota.
Results
Independent of weight loss, oligofructose improved liver steatosis relative to placebo and improved overall NAS score (
P
= 0.016).
Bifidobacterium
was enhanced by oligofructose, whereas bacteria within
Clostridium
cluster XI and I were reduced with oligofructose (
P
< 0.05). There were no adverse side effects that deterred individuals from consuming oligofructose for treatment of this disease.
Conclusions
Independent of other lifestyle changes, prebiotic supplementation reduced histologically-confirmed steatosis in patients with NASH. Larger follow-up studies are warranted.
Clinical Trial
This trial was registered at Clinicaltrials.com as NCT03184376.</description><identifier>ISSN: 1436-6207</identifier><identifier>EISSN: 1436-6215</identifier><identifier>DOI: 10.1007/s00394-018-1721-2</identifier><identifier>PMID: 29779170</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Biopsy ; Body composition ; Body weight ; Body weight loss ; Chemistry ; Chemistry and Materials Science ; Clinical trials ; Diabetes mellitus ; Fatty liver ; Female ; Fibrosis ; Glucose tolerance ; Humans ; Inflammation ; Intestinal microflora ; Liver ; Liver diseases ; Male ; Microbiota ; Middle Aged ; Non-alcoholic Fatty Liver Disease - drug therapy ; Nutrition ; Oligosaccharides - therapeutic use ; Original Contribution ; Pathophysiology ; Pilot Projects ; Prebiotics ; Prebiotics - administration & dosage ; Steatosis ; Supplements ; Treatment Outcome</subject><ispartof>European journal of nutrition, 2019-06, Vol.58 (4), p.1735-1745</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>European Journal of Nutrition is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-4245c9f6d5e7f25fced7af1f5234020f703bdb99c9fdfd1d507c734fb9171bc23</citedby><cites>FETCH-LOGICAL-c372t-4245c9f6d5e7f25fced7af1f5234020f703bdb99c9fdfd1d507c734fb9171bc23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29779170$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bomhof, Marc R.</creatorcontrib><creatorcontrib>Parnell, Jill A.</creatorcontrib><creatorcontrib>Ramay, Hena R.</creatorcontrib><creatorcontrib>Crotty, Pam</creatorcontrib><creatorcontrib>Rioux, Kevin P.</creatorcontrib><creatorcontrib>Probert, Chris S.</creatorcontrib><creatorcontrib>Jayakumar, Saumya</creatorcontrib><creatorcontrib>Raman, Maitreyi</creatorcontrib><creatorcontrib>Reimer, Raylene A.</creatorcontrib><title>Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial</title><title>European journal of nutrition</title><addtitle>Eur J Nutr</addtitle><addtitle>Eur J Nutr</addtitle><description>Purpose
In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophysiology of NASH is unknown, it is believed that the gut microbiota-liver axis influences the development of this disease. With few treatment strategies available for NASH, exploration of gut microbiota-targeted interventions is warranted. We investigated the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH.
Methods
In a placebo-controlled, randomized pilot trial, 14 individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] were randomized to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. The primary outcome measure was the change in liver biopsy NAS score and the secondary outcomes included changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota.
Results
Independent of weight loss, oligofructose improved liver steatosis relative to placebo and improved overall NAS score (
P
= 0.016).
Bifidobacterium
was enhanced by oligofructose, whereas bacteria within
Clostridium
cluster XI and I were reduced with oligofructose (
P
< 0.05). There were no adverse side effects that deterred individuals from consuming oligofructose for treatment of this disease.
Conclusions
Independent of other lifestyle changes, prebiotic supplementation reduced histologically-confirmed steatosis in patients with NASH. Larger follow-up studies are warranted.
Clinical Trial
This trial was registered at Clinicaltrials.com as NCT03184376.</description><subject>Biopsy</subject><subject>Body composition</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Clinical trials</subject><subject>Diabetes mellitus</subject><subject>Fatty liver</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Glucose tolerance</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Intestinal microflora</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Microbiota</subject><subject>Middle Aged</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>Nutrition</subject><subject>Oligosaccharides - therapeutic use</subject><subject>Original Contribution</subject><subject>Pathophysiology</subject><subject>Pilot Projects</subject><subject>Prebiotics</subject><subject>Prebiotics - administration & dosage</subject><subject>Steatosis</subject><subject>Supplements</subject><subject>Treatment Outcome</subject><issn>1436-6207</issn><issn>1436-6215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kUFPwyAUx4nRuDn9AF5MEy9eqg9oi_VmFnUmS7zomVAKGwstE6jGb29rpyYmnoC8Hz9474_QKYZLDMCuAgAtsxTwdYoZwSnZQ1Oc0SItCM73f_bAJugohA0AEFrgQzQhJWMlZjBF1cKE6KxbGSlsYpqtd2-qUW1MnE5a16bCSrd21sgkRCWiW6utiCaakLybuE5EsvWqMi4aeTMcjHUxkda0X77ojbDH6EALG9TJbp2hl_u75_kiXT49PM5vl6mkjMQ0I1kuS13UuWKa5FqqmgmNdU5oBgQ0A1rVVVn2TK1rXOfAJKOZrvpGcCUJnaGL0dv38NqpEHljglTWila5LnACGSEUCjqg53_Qjet82_9uoDChOM-gp_BISe9C8ErzrTeN8B8cAx8C4GMAvA-ADwHwwXy2M3dVo-qfG98T7wEyAqEvtSvlf5_-3_oJ30-RWA</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Bomhof, Marc R.</creator><creator>Parnell, Jill A.</creator><creator>Ramay, Hena R.</creator><creator>Crotty, Pam</creator><creator>Rioux, Kevin P.</creator><creator>Probert, Chris S.</creator><creator>Jayakumar, Saumya</creator><creator>Raman, Maitreyi</creator><creator>Reimer, Raylene A.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RQ</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20190601</creationdate><title>Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial</title><author>Bomhof, Marc R. ; Parnell, Jill A. ; Ramay, Hena R. ; Crotty, Pam ; Rioux, Kevin P. ; Probert, Chris S. ; Jayakumar, Saumya ; Raman, Maitreyi ; Reimer, Raylene A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-4245c9f6d5e7f25fced7af1f5234020f703bdb99c9fdfd1d507c734fb9171bc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biopsy</topic><topic>Body composition</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Clinical trials</topic><topic>Diabetes mellitus</topic><topic>Fatty liver</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Glucose tolerance</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Intestinal microflora</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Microbiota</topic><topic>Middle Aged</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>Nutrition</topic><topic>Oligosaccharides - therapeutic use</topic><topic>Original Contribution</topic><topic>Pathophysiology</topic><topic>Pilot Projects</topic><topic>Prebiotics</topic><topic>Prebiotics - administration & dosage</topic><topic>Steatosis</topic><topic>Supplements</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bomhof, Marc R.</creatorcontrib><creatorcontrib>Parnell, Jill A.</creatorcontrib><creatorcontrib>Ramay, Hena R.</creatorcontrib><creatorcontrib>Crotty, Pam</creatorcontrib><creatorcontrib>Rioux, Kevin P.</creatorcontrib><creatorcontrib>Probert, Chris S.</creatorcontrib><creatorcontrib>Jayakumar, Saumya</creatorcontrib><creatorcontrib>Raman, Maitreyi</creatorcontrib><creatorcontrib>Reimer, Raylene A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Career and Technical Education</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Family Health</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bomhof, Marc R.</au><au>Parnell, Jill A.</au><au>Ramay, Hena R.</au><au>Crotty, Pam</au><au>Rioux, Kevin P.</au><au>Probert, Chris S.</au><au>Jayakumar, Saumya</au><au>Raman, Maitreyi</au><au>Reimer, Raylene A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial</atitle><jtitle>European journal of nutrition</jtitle><stitle>Eur J Nutr</stitle><addtitle>Eur J Nutr</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>58</volume><issue>4</issue><spage>1735</spage><epage>1745</epage><pages>1735-1745</pages><issn>1436-6207</issn><eissn>1436-6215</eissn><abstract>Purpose
In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophysiology of NASH is unknown, it is believed that the gut microbiota-liver axis influences the development of this disease. With few treatment strategies available for NASH, exploration of gut microbiota-targeted interventions is warranted. We investigated the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH.
Methods
In a placebo-controlled, randomized pilot trial, 14 individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] were randomized to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. The primary outcome measure was the change in liver biopsy NAS score and the secondary outcomes included changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota.
Results
Independent of weight loss, oligofructose improved liver steatosis relative to placebo and improved overall NAS score (
P
= 0.016).
Bifidobacterium
was enhanced by oligofructose, whereas bacteria within
Clostridium
cluster XI and I were reduced with oligofructose (
P
< 0.05). There were no adverse side effects that deterred individuals from consuming oligofructose for treatment of this disease.
Conclusions
Independent of other lifestyle changes, prebiotic supplementation reduced histologically-confirmed steatosis in patients with NASH. Larger follow-up studies are warranted.
Clinical Trial
This trial was registered at Clinicaltrials.com as NCT03184376.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29779170</pmid><doi>10.1007/s00394-018-1721-2</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1436-6207 |
| ispartof | European journal of nutrition, 2019-06, Vol.58 (4), p.1735-1745 |
| issn | 1436-6207 1436-6215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2042230632 |
| source | Springer Nature; SPORTDiscus with Full Text |
| subjects | Biopsy Body composition Body weight Body weight loss Chemistry Chemistry and Materials Science Clinical trials Diabetes mellitus Fatty liver Female Fibrosis Glucose tolerance Humans Inflammation Intestinal microflora Liver Liver diseases Male Microbiota Middle Aged Non-alcoholic Fatty Liver Disease - drug therapy Nutrition Oligosaccharides - therapeutic use Original Contribution Pathophysiology Pilot Projects Prebiotics Prebiotics - administration & dosage Steatosis Supplements Treatment Outcome |
| title | Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A52%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histological%20improvement%20of%20non-alcoholic%20steatohepatitis%20with%20a%20prebiotic:%20a%20pilot%20clinical%20trial&rft.jtitle=European%20journal%20of%20nutrition&rft.au=Bomhof,%20Marc%20R.&rft.date=2019-06-01&rft.volume=58&rft.issue=4&rft.spage=1735&rft.epage=1745&rft.pages=1735-1745&rft.issn=1436-6207&rft.eissn=1436-6215&rft_id=info:doi/10.1007/s00394-018-1721-2&rft_dat=%3Cproquest_cross%3E2041231540%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-4245c9f6d5e7f25fced7af1f5234020f703bdb99c9fdfd1d507c734fb9171bc23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2041231540&rft_id=info:pmid/29779170&rfr_iscdi=true |